DEF: Glucotrack Seeks Shareholder Nod for $20M Equity Raise

Glucotrack, Inc. calls a Special Meeting to approve the issuance of over 20% of its common stock to Sixth Borough Capital Fund, LP for a $20 million equity financing facility.

Summary

• A Special Meeting of Stockholders will be held exclusively online on Friday, October 31, 2025, at 12:00 p.m. (Eastern Time).
• Stockholders of record as of September 23, 2025, are entitled to vote.
• The primary purpose is to approve the full issuance of common stock to Sixth Borough Capital Fund, LP under a Purchase Agreement, which may exceed 20% of the Company's outstanding shares, as required by Nasdaq Listing Rule 5635(d).
• The Purchase Agreement allows the Company to sell up to $20.0 million of its common stock to Sixth Borough over a 24-month term.
• The agreement includes an issuance of 60,000 Commitment Shares to Sixth Borough as a fee.
• Shares can be purchased through Regular Purchases (up to 20,000 shares, increasing to 30,000 based on price, max $500,000 per purchase) at 97% of VWAP or the average of the three lowest closing prices.
• Add-On Purchases allow for up to three times the Regular Purchase amount or 30% of trading volume, at 95% of VWAP or the average of the three lowest closing prices.
• Intraday Purchases allow for up to three per day, not exceeding 100% of 5-day average daily trading volume or $1,000,000, at 95% of the lowest transaction price or the previous day's closing price.
• As of September 23, 2025, there were 899,410 shares of common stock outstanding.
• Without stockholder approval, the Company is limited to issuing 179,792 shares (19.99% of outstanding shares) unless the average price per share equals or exceeds $4.63.
• To fully utilize the $20.0 million facility, approximately 3,341,378 shares would need to be issued (based on September 22, 2025 closing price), significantly exceeding the 20% threshold.
• The Board of Directors unanimously recommends voting FOR both the Issuance Proposal and an Adjournment Proposal, which would allow the meeting to be postponed if more time is needed to solicit proxies.

Sentiment

Score: 6

Explanation: The filing outlines a necessary procedural step to secure a significant, flexible capital source, which is positive for the Company's long-term operational stability and strategic initiatives. However, the potential for substantial shareholder dilution at discounted prices presents a notable negative for existing investors. The unanimous board recommendation provides a degree of confidence, but the need for an adjournment proposal suggests some uncertainty in immediate shareholder consensus.

Positives

• The Purchase Agreement provides a potential source of capital of up to $20.0 million, enhancing the Company's financial flexibility.
• The Company gains the ability to access capital when and as needed over a 24-month period.
• The Board of Directors unanimously recommends approval, indicating management's confidence in the strategic benefit of this financing mechanism.

Negatives

• Approval of the Issuance Proposal will lead to significant potential dilution for existing stockholders, as the Company may issue shares representing more than 20% of its outstanding common stock (potentially 3,341,378 shares).
• Shares will be issued at a discount to market prices (95-97% of VWAP or lowest closing prices), which could negatively impact the value of existing shares.
• The inclusion of an Adjournment Proposal suggests potential uncertainty regarding sufficient stockholder support for the Issuance Proposal.

Risks

• Failure to obtain stockholder approval for the Issuance Proposal would limit the Company's ability to raise capital under the Purchase Agreement to 179,792 shares, unless the average price per share issued equals or exceeds $4.63.
• The issuance of a substantial number of new shares will have a dilutive effect on the voting power and economic rights of current stockholders.
• The pricing mechanism for share purchases (discounts to VWAP or lowest closing prices) could result in shares being sold at unfavorable prices, further exacerbating dilution.

Future Outlook

The Company anticipates that the Purchase Agreement will provide a flexible source of capital for 24 months, allowing it to access funds as needed. Management intends to move to adjourn the Special Meeting if insufficient votes are secured for the Issuance Proposal, indicating a proactive approach to ensure the financing can proceed.

Management Comments

• "The Board of Directors unanimously recommends that stockholders vote FOR Proposals 1 and 2."
• "Our Board has determined that the Purchase Agreement with Sixth Borough is in the best interests of the Company and its stockholders because the right to sell shares to Sixth Borough provides the Company with a potential source of capital and the ability to access that capital when and as needed."

Industry Context

This filing describes a common equity financing strategy, often referred to as an 'at-the-market' (ATM) facility or equity line, utilized by smaller public companies, particularly in sectors like medical devices or biotechnology (implied by 'Glucotrack'), to secure ongoing capital. Such facilities offer flexibility in raising funds without the immediate, large-scale dilution or fixed costs of a traditional underwritten offering. The need for shareholder approval for issuances exceeding 20% of outstanding shares is a standard compliance requirement under Nasdaq listing rules, ensuring transparency and investor protection for significant capital raises.

Stakeholder Impact

• Shareholders: Face potential significant dilution of their ownership percentage, voting power, and economic rights due to the issuance of new shares at a discount to market prices.
• Company: Gains access to a flexible capital source of up to $20.0 million, which can be used to fund operations, research and development, or other strategic initiatives, improving liquidity and financial stability.
• Sixth Borough Capital Fund, LP: Will acquire shares at a discount, potentially increasing its beneficial ownership in the Company and providing a return on its investment.

Next Steps

• Stockholders will vote on the Issuance Proposal and Adjournment Proposal at the Special Meeting on October 31, 2025.
• If the Issuance Proposal is approved, the Company will be able to issue shares to Sixth Borough Capital Fund, LP under the Purchase Agreement beyond the 19.99% threshold.
• The Company will file a Current Report on Form 8-K with the SEC within four business days after the Special Meeting to announce the voting results.
• If the Adjournment Proposal is approved and deemed necessary, the Board may adjourn the Special Meeting to solicit additional proxies.

Key Dates

Recommendation

The filing details a necessary step for Glucotrack to secure a flexible capital source of up to $20.0 million, which is crucial for a growth-oriented company. However, the approval of the Issuance Proposal will lead to significant shareholder dilution as shares will be issued at a discount to market prices. While the capital infusion is positive for the company's operational runway, the dilutive effect warrants a cautious 'hold' stance for existing investors, awaiting further clarity on how the capital will be deployed and its impact on future growth and profitability. New investors might consider the entry point based on the future prospects enabled by this capital, but the immediate implications are mixed.

Keywords

Glucotrack, Equity Financing, Capital Raise, Special Meeting, Stockholder Approval, Nasdaq Listing Rule 5635(d), Share Dilution, Purchase Agreement, Sixth Borough Capital Fund, Common Stock, Proxy Statement